Back to Authors

AbiMansour, Jad

0000-0001-8776-588X

Mayo Clinic

Mayo Clinic

Citations 4

Post-ERCP pancreatitis after self-expanding metal stent placement in patients with pancreatic versus non-pancreatic malignant biliary obstruction
AbiMansour, Jad P. , Petersen, Bret T. , Valls, Eric J. Vargas, Law, Ryan, Han, Samuel, AbiMansour, Jad , Vargas Valls, Eric J, Petersen, Bret T. , Vargas, Eric J. , Law, Ryan, Chandrasekhara, Vinay

Therapeutic Advances in Gastrointestinal Endoscopy | June 23, 2026 | Volume: 19 | Issue: No issue available | Pages: No page available

10.1177/26317745261458987 Get It

Background: Self-expanding metal stents (SEMS) are recommended for the endoscopic palliation of distal malignant biliary obstruction (DMBO). Placement of SEMS during endoscopic retrograde cholangiopancreatography (ERCP) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Objectives: The aim of this study is to evaluate rates of PEP in patients who underwent SEMS placement for pancreatic versus non-pancreatic malignancy. Design: Retrospective Cohort Study. Methods: Patients who underwent SEMS placement for DMBO between June 2017 and May 2021 were identified retrospectively from a procedural billing database. PEP incidence was compared between pancreatic and non-pancreatic DMBO groups and multivariate logistic regression was performed to identify risk factors for PEP. Results: A total of 488 individuals were identified, with 395 (80.9%) cases of DMBO due to pancreatic and 93 (19.1%) due to non-pancreatic malignancy. Stent types included 124 (25.4%) fully covered (FCSEMS) and 364 (74.6%) uncovered metal stents (UCSEMS). The overall rate of PEP in the cohort was 6.3% with no significant difference between pancreatic and non-pancreatic etiologies (6.1% vs 7.5%, p = 0.606). When adjusted for age <50 years old, female sex, and pancreatic stent placement, a non-pancreatic malignancy was not associated with an increased risk of PEP (OR 0.83, 95% CI 0.36–2.15). Conclusion: No statistically significant difference in PEP rates was seen after biliary sphincterotomy and SEMS placement for palliation of DMBO in patients with pancreatic versus non-pancreatic malignancies.
Impact of Size on Endoluminal Approaches to Submucosal Tumors of the Stomach
AbiMansour, Jad P. , AbiMansour, Jad

Foregut: The Journal of the American Foregut Society | November 6, 2024 | Volume: 5 | Issue: 1 | Pages: 52-58

10.1177/26345161241295378 Get It

Gastric subepithelial lesions (SELs) represent a heterogenous group of mass lesions that arise from the gastric mucosa. Several endoscopic techniques can be used to manage gastric SELs once the decision is made to pursue resection, including endoscopic submucosal resection, endoscopic submucosal dissection, submucosal tunnel endoscopic resection, and endoscopic full-thickness resection. In addition to other clinical and anatomic factors, lesion size has important implications on the ability to obtain a complete resection while minimizing risk of adverse events. This article reviews technical considerations and available data regarding how size may impact the endoscopic approach to gastric SEL resection.
Histologic analysis of pancreatic cystic lesions: Is tissue the issue?
AbiMansour, Jad P. , Law, Ryan , AbiMansour, Jad

Endoscopy International Open | March 7, 2024 | Volume: 12 | Issue: 03 | Pages: E341-E343

10.1055/a-2241-8038 Get It

Risk of post-sphincterotomy bleeding in patients with thrombocytopenia
AbiMansour, Jad P. , Garimella, Vishal, Petersen, Bret T. , Law, Ryan , Martin, John A. , Levy, Michael J. , Law, Ryan J, AbiMansour, Jad , Petersen, Bret T. , Storm, Andrew C. , Dayyeh, Barham K. Abu , Chandrasekhara, Vinay

Therapeutic Advances in Gastrointestinal Endoscopy | September 25, 2023 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/26317745231200971 Get It

Background: Reports suggest that the rate of adverse events (AEs) post-endoscopic sphincterotomy (ES) to be as high as 10%, with gastrointestinal bleeding being most common after post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Objective: The aim of this study was to characterize the incidence of bleeding in patients with thrombocytopenia following ES. Design: Retrospective observational cohort study. Methods: Patients with thrombocytopenia (defined as <150,000 platelets/μL) who underwent ES between May 2017 and December 2020 were identified at a tertiary care medical center. The incidence of immediate (intraprocedural oozing >5 min or requiring intervention) or delayed (clinical bleeding with associated hemoglobin drop within 14 days) post-ES bleeding was determined via manual chart review. Results: A total of 221 patients with a mean platelet count of 108,000 ± 13,000 platelets/μL underwent ERCP with ES. Immediate bleeding occurred in 11 (5%) patients with no significant drop in hemoglobin or transfusion requirement. Two patients (0.9%), both of whom were noted to have immediate bleeding, also developed delayed bleeding. Presence of malignancy was associated with an increased risk of bleeding (36.4% versus 11.4%, p = 0.037) while platelet count was not. Conclusion: In a cohort of patients with thrombocytopenia, rates of immediate and delayed bleeding are similar to previously reported AE rates of ES in the general patient population. Careful attention should be given to patients with a history of active malignancy as well as those who develop immediate bleeding as they appear to be at increased risk for bleeding complications.